VolitionRx, Alcyomics Win $1M for Inflammatory Response Marker Project | GenomeWeb

NEW YORK (GenomeWeb News) – The Belgian diagnostics developer VolitionRx and the UK-based preclinical drug safety testing firm Alcyomics will use a €779,493 ($1 million) grant to develop biomarkers for indicating inflammatory response, the companies said today.

Under the initiative, the partners will seek to identify novel epigenetic biomarkers for early inflammation and rejection responses linked to graft-versus host disease, which can cause complications in hematopoietic stem cell transplantation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.